Summit Corporation PLC Press Release - Repeat Dosing of SMT C1100 for DMD meets Endpoints in phase 1 trial - View News Article - Action Duchenne - Fighting for a cure for muscular dystrophy: Oxford, UK, 7 November 2012 - Summit (AIM: SUMM), a UK drug discovery company,
announces that the repeat dosing of the utrophin upregulator SMT C1100 for the
treatment of the fatal muscle-wasting disease Duchenne Muscular Dystrophy
('DMD') has successfully met the endpoints as part of a Phase 1 clinical trial
in healthy volunteers. The trial evaluated a new formulation of SMT C1100 and
the results showed that upon repeat dosing, concentrations of the drug achieved
in the blood plasma, stabilised at levels that from preclinical studies are
expected to significantly increase utrophin protein production. The new
formulation was also shown to be safe and well-tolerated in this Phase 1 trial.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment